Can Ozempic, Wegovy, Mounjaro, and Other GLP-1 Medications Help Reduce Opioid Cravings and Support Recovery?
If you or someone you know is experiencing an opioid overdose, call 911 immediately. Naloxone (Narcan) can reverse opioid overdose and is available without a prescription in most US states. For addiction support and treatment referrals, contact SAMHSA’s National Helpline at 1-800-662-4357, free and confidential, 24 hours a day.
Opioid use disorder is a chronic medical condition that has produced one of the most devastating public health crises of the past three decades. Opioid-related overdose deaths have claimed hundreds of thousands of lives in the United States alone since the late 1990s, driven by prescription opioids, heroin, and the arrival of illicitly manufactured fentanyl and its analogues. Despite the existence of effective pharmacological treatments — buprenorphine, methadone, naltrexone — access barriers, stigma, and the neurobiological tenacity of opioid addiction mean that many people with opioid use disorder do not receive adequate treatment or cannot sustain recovery through multiple relapse cycles.
Into this landscape has come a research question that would have seemed implausible a decade ago: could medications designed to regulate blood sugar and drive weight loss play a role in treating opioid addiction? The answer, from a growing body of preclinical research, is that GLP-1 receptor activation may reduce opioid reward, drug-seeking behavior, and relapse in animal models through mechanisms that are biologically distinct from existing opioid treatments. Whether that preclinical signal translates into clinically meaningful benefit in humans is what the field is actively working to establish.
This article covers the opioid-specific evidence in depth. The broader framework — why GLP-1 receptor activation in the brain’s reward circuitry might reduce the compulsive drive toward addictive substances generally — is covered in the GLP-1 drugs and dopamine article, which is the recommended starting point for understanding the mechanism.
GLP-1 medications are not approved to treat opioid use disorder. Buprenorphine, methadone, and naltrexone are life-saving, FDA-approved treatments for OUD. Do not stop or reduce prescribed addiction medications without medical guidance.
The Scale of Opioid Use Disorder
Opioid use disorder affects tens of millions of people worldwide and has produced overdose mortality at a scale without precedent in the history of substance addiction. In the United States, more than 80,000 opioid-related overdose deaths occurred in 2023, the large majority involving illicitly manufactured fentanyl. The neurobiological features that make opioid addiction so lethal and so treatment-resistant are also what make new pharmacological approaches so urgently needed: the severity of withdrawal, the durability of cue-triggered relapse even after extended abstinence, the high overdose risk during relapse attempts following periods of tolerance reduction, and the frequent co-occurrence of chronic pain, psychiatric comorbidity, and social deprivation that complicate recovery.
Medication-assisted treatment with buprenorphine, methadone, or naltrexone dramatically reduces overdose mortality and improves long-term outcomes. These medications are effective and underused: the majority of people with opioid use disorder in the United States do not receive them, due to treatment access barriers, stigma, regulatory restrictions, and patient-level factors. A complementary pharmacological approach — one that reduces the rewarding and craving dimensions of opioid use through a mechanism entirely different from existing treatments — would address an unmet need even if it could not replace established therapies.
How Opioids Affect the Brain
Opioids produce their effects by binding to mu-opioid receptors, which are distributed throughout the brain, spinal cord, and peripheral nervous system. Mu-opioid receptor activation produces pain relief, sedation, respiratory depression, and — critically for addiction — euphorically reinforcing effects through indirect dopamine release in the nucleus accumbens.
The reinforcing pathway runs as follows: opioids bind to mu-opioid receptors on inhibitory interneurons in the ventral tegmental area, disinhibiting the dopamine-producing neurons those interneurons normally suppress. The result is a surge of dopamine release in the nucleus accumbens that is substantially larger than any natural reward produces. This dopamine surge teaches the brain that opioid use is among the most rewarding experiences available, creating the neurological foundation of addiction: powerful anticipatory craving, cue-conditioned wanting, and the progressive neuroadaptation that makes natural rewards seem flat by comparison.
With repeated exposure, the brain adapts: opioid receptors are downregulated, endogenous opioid production decreases, and the neurological set point shifts so that normal functioning requires the drug. This is the physiology of dependence and withdrawal. More durably, the mesolimbic dopamine system is sensitised to opioid-associated cues in ways that persist for months or years after abstinence, producing the cue-triggered relapse that represents the most clinically challenging dimension of long-term recovery.
Why GLP-1 Receptors Are Relevant to Opioid Addiction
GLP-1 receptors are expressed in the ventral tegmental area, nucleus accumbens, prefrontal cortex, amygdala, and hippocampus — the same circuit that opioids hijack to produce their reinforcing effects. This anatomical overlap is the biological basis for the research hypothesis. When GLP-1 receptor agonists activate receptors in these regions, they appear to modulate dopaminergic and possibly opioid-related signaling in ways that reduce the reward value of addictive stimuli, blunt cue-triggered wanting, and potentially reduce the stress-induced reinstatement of drug-seeking. The precise mechanism through which GLP-1 receptor activation affects opioid-specific reward processing is different from how it affects alcohol or food reward, reflecting the opioid system’s distinct upstream activation of dopamine release. GLP-1 receptor activation is not blocking opioid receptors — that is naltrexone’s mechanism. Instead, it appears to influence the downstream dopaminergic consequence of opioid receptor activation in the reward circuit.
The possibility that a single pharmacological mechanism could reduce reward-driven craving across multiple addictive substances reflects the shared dopaminergic substrate of those substances, not any opioid-specific effect of GLP-1 receptor activation. This cross-substance breadth is one of the most scientifically interesting features of the GLP-1 and addiction research program.
What Animal Studies Show
The preclinical evidence for GLP-1 receptor agonists and opioid use disorder is less extensive than for alcohol and cocaine, but the available studies are consistent in direction and plausible in mechanism.
Across multiple experimental designs and multiple GLP-1 receptor agonist compounds, animal studies have found:
- Reduced voluntary opioid self-administration — animals given access to opioids through a lever-press mechanism chose to press the lever less frequently when receiving GLP-1 receptor agonist treatment
- Reduced opioid-conditioned place preference — animals showed less preference for environments previously associated with opioid reward
- Reduced cue-induced reinstatement of opioid-seeking after abstinence — the triggers that reliably produce relapse-like behavior in control animals were less effective in GLP-1-treated animals
- Reduced stress-induced reinstatement — stress-triggered drug-seeking, one of the most clinically significant relapse mechanisms, was attenuated following GLP-1 receptor agonist treatment in some models
The cue-reinstatement and stress-reinstatement findings are the most clinically relevant, because these are the behavioral patterns that predict real-world relapse in humans and that existing treatments address least reliably. If GLP-1 receptor activation genuinely reduces the capacity of opioid-associated cues and stress states to trigger drug-seeking, even in a partial way, that would represent a meaningful clinical contribution to the relapse prevention challenge that defines opioid use disorder treatment.
Preclinical findings in opioid addiction models are encouraging but more limited in volume and consistency than the alcohol and cocaine literature. The opioid system’s complex interaction with GLP-1 signaling may produce different dynamics than other addictive substances, and the human evidence required to confirm clinical relevance is still very early-stage.
Human Evidence: What Exists and What It Can Establish
Human evidence for GLP-1 drugs in opioid use disorder is at the earliest stage of the research hierarchy. What exists consists primarily of observational analyses from healthcare databases, case reports, and the inferential extrapolation from the broader addiction neuroscience findings.
Observational studies comparing patients on GLP-1 medications to those on alternative diabetes treatments have found lower rates of opioid-related diagnoses and opioid-related healthcare events in GLP-1 drug users in some analyses. These findings are subject to substantial confounding: patients prescribed GLP-1 drugs differ from those on other treatments in healthcare access, metabolic health, and multiple other characteristics that might independently affect substance use outcomes. They are hypothesis-generating findings, not evidence of effectiveness.
The human clinical trial pipeline for GLP-1 drugs in opioid use disorder is less advanced than for alcohol and nicotine, reflecting both the higher regulatory complexity of opioid research and the relative novelty of the hypothesis in this specific indication. Several research groups are in the process of designing or initiating trials, but as of 2026, robust randomised controlled trial data in opioid use disorder specifically does not exist. This is the most important limitation to state clearly: the gap between preclinical promise and clinical evidence is larger for opioid use disorder than for any other substance covered in this hub.
How GLP-1 Drugs Differ From Existing OUD Treatments
Understanding what GLP-1 receptor activation might offer to patients with opioid use disorder requires situating it clearly relative to what buprenorphine, methadone, and naltrexone already do.
Buprenorphine and Methadone
Buprenorphine (a partial mu-opioid agonist) and methadone (a full mu-opioid agonist) treat opioid use disorder by providing a stable, controlled level of opioid receptor activation that prevents withdrawal, reduces craving, and blocks the euphoric effects of illicit opioids. They work directly through the mu-opioid receptor system. Their effectiveness in reducing overdose mortality is among the most robustly established findings in addiction medicine. GLP-1 receptor agonists do not work through the opioid receptor system and cannot replace the receptor-level stabilisation that buprenorphine and methadone provide.
Naltrexone
Naltrexone blocks mu-opioid receptors, preventing opioid drugs from producing euphoria and reducing the reward of opioid use through competitive receptor antagonism. Extended-release naltrexone is effective for patients who are fully detoxified and motivated to maintain abstinence. Interestingly, naltrexone’s opioid receptor blockade and GLP-1 receptor activation both ultimately target the mesolimbic dopamine system through different upstream mechanisms — naltrexone by preventing opioids from disinhibiting dopamine neurons, GLP-1 receptor agonists by directly modulating dopamine signaling in reward circuits. If both mechanisms are additive, combination therapy could theoretically offer greater benefit than either alone. This is a hypothesis that has not been tested in clinical trials.
The Potential Complementary Role
The most plausible clinical role for GLP-1 drugs in opioid use disorder, if clinical trials confirm their effectiveness, is as an adjunct to established treatment rather than a replacement. The same patient on buprenorphine and GLP-1 therapy simultaneously would be receiving receptor-level opioid stabilisation from buprenorphine and reward circuit modulation from GLP-1 receptor activation — addressing overlapping but distinct dimensions of the neurobiological problem. Whether this combination produces meaningful additional benefit is what clinical research will need to establish. The broader addiction overview in the substance use disorders article covers the general framework for how GLP-1 drugs might fit alongside existing treatments.
The Metabolic Health Dimension: A Distinctive Advantage
One clinically distinctive advantage of GLP-1 therapy for patients with opioid use disorder is its potential to address the substantial metabolic burden that frequently accompanies this condition. People with opioid use disorder have elevated rates of obesity, Type 2 diabetes, cardiovascular disease, fatty liver disease, and metabolic syndrome — partly reflecting the biological consequences of chronic opioid use, partly the social determinants that co-occur with addiction, and partly the appetite-increasing effects of opioids themselves. Some opioid agonist treatments, particularly methadone, are associated with weight gain and increased metabolic risk.
A medication that simultaneously reduces opioid craving (if proven effective), improves glycaemic control, supports weight management, and reduces cardiovascular risk would address several dimensions of the overall health burden of opioid use disorder in a single treatment. This represents a different kind of clinical value from simply adding another addiction pharmacotherapy, and it makes GLP-1 therapy potentially important for patients with OUD even before its addiction-specific effectiveness is established.
Safety Considerations in the OUD Population
The established safety profile of GLP-1 drugs in the general population applies in the OUD context, but several specific considerations deserve attention. The gastrointestinal side effects of GLP-1 therapy — nausea, vomiting, and abdominal pain — may be more significant in patients who are also experiencing withdrawal or who have compromised nutritional status. The severe adverse reactions page covers the full adverse event profile of GLP-1 medications.
Drug interactions between GLP-1 receptor agonists and opioid medications, including prescribed buprenorphine and methadone, have not been systematically studied. Given that opioids affect gastrointestinal motility and GLP-1 drugs slow gastric emptying, there may be physiological interactions that affect the absorption and timing of both drugs in ways that have clinical implications. Healthcare providers managing patients with OUD who are also receiving GLP-1 therapy should be alert to these potential interactions and monitor carefully.
Frequently Asked Questions
Can Ozempic treat opioid addiction?
No. Ozempic is not approved to treat opioid use disorder. Researchers are investigating whether GLP-1 receptor agonists may reduce opioid reward and drug-seeking behavior, with encouraging results from animal studies, but human clinical trial evidence is limited. Established treatments — buprenorphine, methadone, naltrexone — remain the standard of care and should not be discontinued or substituted.
Do GLP-1 drugs block opioid receptors like naltrexone?
No. GLP-1 receptor agonists do not block opioid receptors. Their mechanism of action is entirely different from naltrexone: rather than preventing opioids from binding to their receptors, GLP-1 receptor activation appears to modulate the downstream dopaminergic reward signaling in mesolimbic circuits. Both mechanisms ultimately target the reward system, but through different pharmacological pathways.
Can I take Ozempic or Wegovy while on buprenorphine?
There is no established contraindication to taking GLP-1 medications alongside buprenorphine for patients who qualify for GLP-1 therapy for metabolic indications. However, drug interactions between GLP-1 drugs and opioid medications have not been systematically studied. Any patient with OUD who is considering GLP-1 therapy should discuss it with both their addiction medicine specialist and their prescribing physician.
Will GLP-1 drugs make opioid withdrawal worse?
There is no established evidence that GLP-1 drugs worsen opioid withdrawal. The GI side effects of GLP-1 therapy — particularly nausea and vomiting — could compound the discomfort of withdrawal symptoms if they overlap. Clinical management should consider the timing of GLP-1 therapy initiation relative to the withdrawal and stabilisation phase of OUD treatment.
Why is the evidence for opioids weaker than for alcohol?
The alcohol and GLP-1 research program has a longer history, more research groups actively working on it, and the clinical trial infrastructure is more advanced. Opioid addiction research faces additional regulatory complexity, and the mechanistic interaction between GLP-1 signaling and the opioid system is more complex than the GLP-1 and alcohol interaction. The evidence is at an earlier stage, not because the hypothesis is weaker.
Should someone with opioid use disorder use GLP-1 drugs to help them quit?
No one with opioid use disorder should attempt to manage their condition with GLP-1 medications rather than established treatment. Opioid use disorder is a serious medical condition with life-threatening consequences, and its treatment should be supervised by qualified addiction medicine specialists using evidence-based approaches. If GLP-1 therapy is appropriate for a metabolic indication, that can be discussed with the treatment team as part of a comprehensive care plan.
Key Takeaways
The GLP-1 and opioid addiction research represents one of the most important and most challenging frontiers in the broader addiction neuroscience program. The most important points from this article are:
- Opioid use disorder involves mu-opioid receptor-mediated disinhibition of mesolimbic dopamine neurons, producing reward signals that are among the most powerful the brain can generate — and GLP-1 receptors are expressed in the same circuit
- Animal studies show consistent reductions in opioid self-administration, conditioned place preference, cue-induced reinstatement, and stress-induced relapse following GLP-1 receptor agonist treatment
- Human evidence is very limited — the opioid-specific clinical trial data is less advanced than for alcohol or nicotine, and observational data cannot establish causation
- GLP-1 receptor agonists do not work through the opioid receptor system and cannot replace buprenorphine, methadone, or naltrexone; the most plausible clinical role, if clinical trials confirm efficacy, is as an adjunct to existing treatment
- The metabolic health benefits of GLP-1 therapy may be clinically significant for patients with OUD regardless of whether the addiction-specific effects are confirmed
- Drug interactions between GLP-1 medications and opioid treatments have not been systematically studied and should be discussed with treating physicians
- Do not discontinue prescribed addiction medications without medical guidance; SAMHSA’s National Helpline (1-800-662-4357) can assist with treatment referrals